Pyxis Oncology, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Pyxis is a clinical-stage oncology company with no product revenue; it reported operating expenses and losses as it advances its pipeline.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None generated to date | |||
| Research and development expense | $11.4 million | $17.2 million | $23.3 million | $37.2 million |
| General and administrative expense | $6.7 million | $8.6 million | $15.8 million | $19.9 million |
| Total operating expenses | $18.1 million | $25.7 million | $39.1 million | $57.1 million |
| Net loss | $15.9 million | $25.6 million | $35.1 million | $56.9 million |
| Net loss per share, basic and diluted | $0.41 | $0.79 | $0.95 | $1.76 |
Margins are not meaningful because the company has no revenue. Q2 other income was $2.2 million, including $1.7 million of interest and investment income and $0.6 million of sublease income; this reduced the reported net loss relative to operating loss.
- Cash and investments: $142.7 million at June 30, 2023, comprising $25.9 million cash and cash equivalents and $116.8 million short-term U.S. Treasury securities. Restricted cash was an additional $1.5 million.
- Cash flow, six months: $37.9 million used in operations, versus $51.4 million in 2022; $121.6 million used in investing, primarily reflecting purchases of marketable securities and property and equipment; $6.1 million provided by financing, mainly ATM proceeds.
- Debt and liquidity: No borrowings are reported. Total liabilities were $30.0 million, including operating lease liabilities; current assets were $149.3 million and current liabilities $9.2 million.
- Equity and dilution: Stockholders’ equity was $145.3 million. Common shares outstanding were 39.4 million at June 30, up from 35.0 million at December 31, 2022. The company sold about 1.0 million shares through its ATM program for $6.3 million gross and issued 1.8 million shares to Pfizer under its license agreement.
Changes versus prior comparable periods
- Q2 operating expenses decreased $7.6 million and net loss narrowed $9.7 million year over year. Six-month operating expenses fell $18.0 million and net loss narrowed $21.8 million.
- Lower R&D program costs drove much of the decline: prior-year periods included manufacturing costs and, for the six-month comparison, a $10.0 million Biosion license payment. These savings were partly offset by higher personnel costs and clinical-trial spending as PYX-201 and PYX-106 advanced.
- Interest and investment income rose substantially with higher interest rates and Treasury discount accretion. Sublease income also began in 2023.
- Cash and cash equivalents fell sharply from $179.3 million at year-end, while the company invested cash in short-term Treasuries; total cash, cash equivalents and short-term investments were $142.7 million at June 30.
Outlook, developments and risks
- Management estimated that existing cash, cash equivalents and short-term investments would fund operations and capital requirements into the first half of 2025, subject to assumptions and potential changes in plans. The financial-statement note separately says resources are expected to cover at least twelve months from issuance. The company expects continued losses and may need additional financing.
- PYX-201 is in a Phase 1 dose-escalation trial; dosing was ongoing at the third dose level, and the company anticipated preliminary data, including biomarkers and early activity signals, in early 2024. The FDA granted it Orphan Drug Designation for pancreatic cancer in May 2023.
- PYX-106 began its Phase 1 trial in Q2; preliminary data were anticipated in late 2023. Both programs remain early-stage, and clinical results and regulatory approval are uncertain.
- The company agreed to acquire Apexigen in a stock transaction, expected to close later in August 2023 subject to customary conditions, including Apexigen stockholder approval. Existing Pyxis holders and certain other equity holders were expected to own about 90% of the combined company, with Apexigen holders and certain other equity holders owning about 10%. The transaction would add sotigalimab, a Phase II candidate, and other assets; cited trial activity and tolerability are not proof of future outcomes.
- Management said PYX-203 and PYX-102 preclinical development had been paused to focus spending on PYX-201 and PYX-106; elsewhere the filing says PYX-202 development was ceased. Verify the program status and any implications for spending.
- Key risks include clinical or manufacturing setbacks, reliance on third-party manufacturers and CROs, need for additional capital and potential dilution, dependence on licensed intellectual property, competitive and regulatory uncertainty, and failure to complete or integrate the Apexigen acquisition. The company reported no material legal proceedings. Disclosure controls were assessed as effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether the Apexigen acquisition closed as expected, its final terms, integration costs and resulting share count.
- Actual clinical-trial enrollment, safety, biomarker and efficacy updates for PYX-201 and PYX-106, and whether reported preliminary timelines were met.
- Cash use against management’s runway estimate, the timing and scale of future financing needs, and potential dilution.
- Manufacturing capacity and supply risks, particularly reliance on outside suppliers and manufacturing in China.
- Current status and resource allocation for paused or discontinued pipeline programs, and potential future license milestones, royalties and other contingent obligations.